We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
The Pan American Health Organization (PAHO) reports continuing widespread transmission of dengue fever in countries in the Americas and the Caribbean.
The following countries have reported cases from 1 January 2023 to 21 August 2023:
Antigua and Barbuda: 28 cases
Argentina: 121 424 cases (65 deaths)
Aruba: 9 cases
Bahamas: 2 cases
Barbados: 274 cases
Belize: 4 450 cases
Bolivia: 137 110 cases (79 deaths)
Brazil: 2 569 746 cases (912 deaths)
Colombia: 67 944 cases (44 deaths)
Costa Rica: 4 480 cases
Dominican Republic: 3 667 cases (4 deaths)
Ecuador: 5 372 cases (5 deaths)
El Salvador: 3 748 cases
Grenada: 543 cases (1 death)
Guadeloupe: 2 236 cases
Guatemala: 10 914 cases (21 deaths)
Guyana: 92 cases
Honduras: 8 607 (4 deaths)
Jamaica : 151 cases
Martinique: 2 599 cases
Mexico: 61 845 cases (13 deaths)
Montserrat: 2 cases
Nicaragua: 75 122 cases (1 death)
Panama : 5 506 cases (1 death)
Paraguay: 7 383 cases (10 deaths)
Peru: 235 014 cases (399 deaths)
Puerto Rico: 472 cases
Saint Barthelemy: 64 cases
Saint Kitts and Nevis: 1 case
Saint Lucia: 14 cases
Saint Martin: 77 cases
Saint Vincent and the Grenadines: 14 cases
Suriname: 76 cases
Trinidad and Tobago: 34 cases
United States of America: 1 case in Texas reported by 16 August 2023. 15 cases in Florida by 19 August 2023.
Uruguay: 35 cases
Venezuela: 4 809 cases (8 deaths)
Virgin Islands (UK): 4 cases
Dengue virus is spread by Aedes mosquito bites and can cause a flu-like illness, sometimes leading to severe or life-threatening disease.
Dengue is an infection found in tropical and sub-tropical climates worldwide.
All travellers to endemic regions are potentially at risk of dengue fever and should be aware of this infection.
Aedes mosquitoes are particularly persistent and aggressive. They bite between dawn and dusk.
A new dengue vaccine Qdenga® has been licensed in the UK and is awaiting JCVI recommendations for use.
Travellers developing a fever during or on return from travel are advised to seek medical attention as soon as possible.
For further information see TRAVAX dengue fever page.
